Table 6.
Comparison of the characteristics of pharmacogenetic subpopulations based on UGT1A1 polymorphism.
| Characteristics |
UGT1A1 Wild Type n = 53 |
UGT1A1 Heterozygous n = 41 |
UGT1A1 Homologous n = 13 |
p-Value | |
|---|---|---|---|---|---|
| Treament Characteristics | |||||
| Induction chemotherapy, n (%) | FOLFIRINOX | 29 (55) | 24 (59) | 2 (15) | 0.059 |
| FOLFOX | 21 (40) | 15 (37) | 10 (77) | ||
| FOLFIRI | 3 (6) | 2 (5) | 1 (8) | ||
| Induction chemotherapy Irinotecan Dose intensity (%), mean | 86 | 83 | 37 | 0.025 | |
| Induction therapy initial radiologic response, n (%) | CR | 1 (2) | 2 (5) | 0 (0) | 0.5 |
| PR | 36 (71) | 32 (80) | 10 (77) | ||
| SD | 10 (20) | 6 (15) | 2 (23) | ||
| PD | 4 (8) | 0 (0) | 0 (0) | ||
| Maintenance chemotherapy regimen, n (%) | Doublet chemotherapy (FOLFOX, FOLFIRI(3), CAPOX) |
14 (29) | 12 (30) | 2 (15) | 0.8 |
| Single chemotherapy (LV5FU2, Capecitabine) | 23 (48) | 20 (50) | 9 (69) | ||
| No chemotherapy | 11 (23) | 8 (20) | 2 (15) | ||
| Irinotecan cumulated dose (mg), mean | 2.932 | 3.290 | 1.556 | 0.13 | |
UGT1A1: uridine diphosphate glucuronosyltransferase; FOLFIRINOX: 5-FU, Irinotecan, Oxaliplatin; FOLFOX: 5-FU and Oxaliplatin; FOLFIRI: 5-FU and Irinotecan; CAPOX: Capecitabine and Oxaliplatin; LV5FU2: 5-FU and Leucovorin; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease. Bold numbers: p < 0.05.